| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| Telephone: | 800-533-1710 |
| International: | +1 855-379-3115 |
| Values are valid only on day of printing | |
| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| Telephone: | 800-533-1710 |
| International: | +1 855-379-3115 |
| Values are valid only on day of printing | |
Resource center
Our commitment
Mayo Clinic Laboratories is committed to working with our communities as we all face the unprecedented challenges of the COVID-19 pandemic. Since early 2020, Mayo Clinic researchers and experts have provided expertise to guide the public health response, and our clinical staff has been on the front lines providing lifesaving care for patients with COVID-19.
Learn more about our COVID-19 testing.
Results that matter
We're dedicated to our patients' health and well-being,
and proud of the outstanding outcomes we achieve.
*Data current as of 4/1/22
6,417,638
molecular tests performed
9
COVID-19 testing platforms implemented
299,582
serology tests performed
24/7
support from Mayo Clinic physicians and scientists
COVID testing
Mayo Clinic Laboratories provides testing and associated support for our clients around the world as they manage the ongoing effects of COVID-19. We offer a comprehensive menu of COVID-19 and related testing, including molecular (PCR) testing to diagnose active COVID-19 infection; serology testing to identify people who previously had COVID-19 or have active immunity; and COVID-19/influenza multiplex testing.
Expertise
Mayo Clinic researchers and experts have played a key role in the global response to COVID-19 — from developing and deploying testing, to providing up-to-date information to the public, to advising government and businesses on the best ways to keep people safe.
Newsroom
Featuring Mayo Clinic Laboratories in the news, as well as the latest COVID-19 podcasts and articles. Keep up to date on testing developments and scientific advances.
COVID-19 focused podcasts
Mayo Clinic experts share their knowledge on the state of testing, vaccines, treatments, and more. Podcasts are hosted by Bobbi Pritt, M.D., chair of Mayo Clinic's Division of Clinical Microbiology.
Resources
Access COVID-19 resources, reference guides, educational content, FAQs, and more.
The Latest
A team of researchers has confirmed that neutralizing monoclonal antibody (nMAb) therapies are associated with reduced risk of adverse outcomes of COVID-19 in high-risk populations. The cohort study, published in JAMA, included more than 167,000 nonhospitalized patients from health care systems based in California, Texas, and Utah, and at Mayo Clinic in Rochester, Minnesota.
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, to discuss broader changes that are unfolding in the national and global diagnostic industry, and what to expect in the coming years.
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, and special guest Susan Van Meter, president of the American Clinical Laboratory Association (ACLA). In celebration of Medical Laboratory Professionals Week, they discuss the critical role laboratories play in patient care and key legislative issues that impact the profession.
While the accelerated innovation and increased access to testing that’s occurred because of the COVID-19 pandemic has been critically important to worldwide health care, so too has the crash course in laboratory testing and pathology the general public has received throughout the entirety of the pandemic.
Matthew Binnicker, Ph.D., director of Mayo Clinic’s Clinical Virology Laboratory, provides insight on the newest COVID-19 subvariant – XBB.1.16, also known as “Arcturus.”